Breadcrumb Home News News archive A news archive from Sobi in North America News archive A news archive from Sobi in North America Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout 06/15/2020 - 16:06 Sobi publishes report for the first quarter 2020 05/05/2020 - 13:24 New research uncovers the toll rare diseases take on relationships 02/28/2020 - 14:02 Load More
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout 06/15/2020 - 16:06
